Mirabegron ( DrugBank: Mirabegron )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	4
13	Multiple sclerosis/Neuromyelitis optica	1
53	Sjogren syndrome	1
226	Interstitial cystitis with Hunners ulcer	2

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03412513 (ClinicalTrials.gov)	July 17, 2017	21/1/2018	Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease	Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial	Overactive Bladder;Parkinson Disease	Drug: Mirabegron;Drug: Placebo	Seoul National University Hospital	NULL	Unknown status	40 Years	80 Years	All	144	Phase 4	Korea, Republic of
2	JPRN-UMIN000043848	2017/01/10	29/04/2021	The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder	The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder : A randomized controlled trial - SEMPDOABRCT	Overactive bladder	Treatment group receiving daily mirabegron 50mg for 12 weeks Placebo group	Al Zahraa Hospital	NULL	Complete: follow-up complete	40years-old	70years-old	Male and Female	110	Not applicable	Asia(except Japan)
3	NCT02536976 (ClinicalTrials.gov)	December 2015	28/8/2015	Mirabegron in Parkinson Disease and Impaired Cognition	A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition	Parkinson Disease;Overactive Bladder;Impaired Cognition	Drug: mirabegron;Drug: Placebo	HealthPartners Institute	NULL	Completed	25 Years	80 Years	All	7	Phase 4	United States
4	NCT02092181 (ClinicalTrials.gov)	March 2014	7/3/2014	A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)	A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)	Parkinsons Disease	Drug: Mirabegron;Drug: Placebo	Daniel Burdick, MD	Astellas Pharma US, Inc.	Completed	30 Years	85 Years	All	30	Phase 4	United States

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02086188 (ClinicalTrials.gov)	May 2014	11/3/2014	Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis	Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)	Multiple Sclerosis	Drug: Mirabegron;Drug: Placebo	Theodore R. Brown, MD MPH	Astellas Pharma Inc	Completed	18 Years	N/A	All	28	Phase 4	United States

53. Sjogren syndrome

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04909255 (ClinicalTrials.gov)	March 23, 2021	21/4/2021	Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder	The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogren's Syndrome Patient	Sjogren's Syndrome;Overactive Bladder Syndrome	Drug: mirabegron;Drug: oxybutynin, tolterodine, solifenacin	China Medical University Hospital	NULL	Recruiting	20 Years	N/A	All	50	Phase 4	Taiwan

226. Interstitial cystitis with Hunners ulcer

Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02787083 (ClinicalTrials.gov)	August 2016	23/5/2016	A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis	A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis	Cystitis, Interstitial	Drug: Mirabegron;Drug: Placebo	Philadelphia Urosurgical Associates	Astellas Pharma Global Development, Inc.	Terminated	18 Years	95 Years	Female	9	Phase 3	United States
2	JPRN-UMIN000008484	2012/07/23	20/07/2012	a	a - a	Interstitial cystitis/ Hypersensitive bladder syndrome	Administration of mirabegron 50mg per day for four weeks.	Department of Urology, Graduate school of medicine, University of Tokyo	NULL	Pending	20years-old	Not applicable	Male and Female	20	Not selected	Japan